Anthony John Iafrate
Harvard University · 861 works · 78,044 citations · h-index 127
Top works
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Detection of large-scale variation in the human genome
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- Anchored multiplex PCR for targeted next-generation sequencing